0

Corporate Presentation

1

Disclaimer

Certain statements in this document are forward looking based on management's current expectations

but actual events may differ materially due to various factors. These statements are related but not

limited to future objectives, plans, status, events, circumstances, progress and outcome of research

and development, potential product attributes, usage, launch dates and sales potential, changes in the

value of rupee and other foreign currencies and environmental changes.

These forward-looking statements based on estimates and the anticipated effects of future events on

current and developing circumstances are subject to numerous risks and uncertainties and are not

necessarily predictive of future results. Actual results may differ materially from those anticipated in the

forward-looking statements.

Jubilant may, from time to time, make additional written and oral forward looking statements, including

statements contained in the company’s filings with the regulatory bodies and our reports to

shareholders. The company assumes no obligation to update forward-looking statements to reflect

actual results, changed assumptions or other factors.

1

• Jubilant Bhartia Group : Valued around US $ 3Bn • Employs around 30,000 people across the globe with ~ 1400 in North America

• Jubilant Bhartia Foundation, a not for profit organisation is a social arm of Jubilant Bhartia Group

• The foundation is engaged in community development work focusing on primary education, basic healthcare, skill development through vocational training for youth & women

• Aims at long term sustainable social intervention by empowering communities through 4P model (Public-Private-People-Partnership)

Pharmaceuticals & Life Sciences

Integrated Outsourcing Solutions Provider for Pharmaceutical & Life Sciences Industry India’s largest CRAMs Company Revenues FY2012: US $ 892 Mn (Rs.4,278 Crs)

Listed on NSE & BSE, India

Leading player in Agri Products in North India, Caters to niche markets in Performance Polymers globally 2nd largest retailer in Bengaluru operating 5 hypermarket-cum-malls

Revenue FY 2012: US $ 207 Mn (Rs. 996 Crs)

Listed on NSE & BSE, India

A master franchise of Domino’s Pizza for India, Bangladesh, Nepal & Sri Lanka and Dunkin’ Donuts for India; Domino’s has presence in 118 cities through over 552 stores in India 8 Dunkin’ Donuts stores opened since May 2012, in Delhi NCR

Revenues FY 2012: US$ 212 Mn (Rs. 1,018 Crs)

Listed on NSE & BSE, India

Engaged in the upstream oil and gas exploration and production sector

Portfolio of 9 blocks in India Producing Asset – Kharsang

Development Asset – KG block Revenues FY 2012: US$ 19.06 Mn (Rs. 92 Crs) Listed in AIM market, London

Aerospace Sole authorized Independent Representative of Bell Helicopter in India for sales, marketing and customer support. Also represent other international aerospace companies. Oil & Gas Services • Consultant to Transocean-

offshore drilling company • Manning and Marketing

services for Tidewater Marine International etc

Agri & Polymers And Retail Food Oil & Gas Services

Exclusive dealership of Audi make cars in Karnataka and Tamil Nadu Service center for Audi cars in Bengaluru and Chennai Custom Paint and Body workshop in Bengaluru

Auto

Jubilant Bhartia Group - Snapshot

3

Jubilant Life Sciences – Overview

* United Nations Conference on Trade And Development report 2010 ** March 2013

• Providing Pharmaceutical & Life Sciences products and services across the pharmaceutical value chain

• Ranked No. 6 amongst top 10 Global Pharma outsourcing players as per UNCTAD* World Investment Report 2011

• Reputed and High Quality relationships with Top 20 Pharma companies, and 7 out of the top 10 Agrochemical companies globally

• Low cost, multi location & vertically integrated supplier

• Employs over 6300 people including 1400 in North America and 1200 in R&D

• Part of Jubilant Bhartia Group, with founders shareholding at 49 %**

Integrated Pharmaceutical

& Life Sciences

Company

‘Partner of Choice’ to Global

Life Sciences Companies

Domestic

30%

International 70%

Revenue Mix by Geography US $ 892 Mn (Rs 4,278crs)

3

4

Global Presence

• Present in India, North America, Europe and China • International sales in 98 countries • 50% assets in North America

Gajraula, Uttar Pradesh Largest integrated pyridine & its derivatives facility in the world

Ambarnath, Maharashtra Pyridine derivatives

Bengaluru, Karnataka State-of-art Discovery Centre

Roorkee, Uttarakhand UKMHRA, USFDA, PMDA, ANVISA approved facility for generics

Samlaya, Gujarat Nutrition Products

Nira, Maharashtra Life Sciences Chemicals

Bharuch, Gujarat SEZ for Nutrition Products and Pyridine derivatives

Nanjangud, Karnataka USFDA, AFSSAPS & PMDA approval APIs manufacturing facility

Noida, Uttar Pradesh Corporate Office & R&D Centres

Kirkland, Quebec, Canada USFDA approved facility for contract manufacturing Non Sterile products and Radiopharmaceuticals

Salisbury, Maryland, USA USFDA approved facility for generics (Tablets & Capsules)

Spokane, Washington, USA USFDA approved facility for contract manufacturing of Sterile injectable and Allergy Therapy Products

Bedminster, New Jersey, USA Clinical Research Centre and Jubilant Life Sciences -Marketing Office

Corporate Office

Branch Offices

Manufacturing Facilities R&D Facilities

Indian Subsidiaries International Subsidiaries

Pune Hyderabad

Chennai

Lucknow

Merelbeke , Belgium Regulatory & Generic Marketing

Shanghai, China Marketing Office

Note: This illustration is not exhaustive. This illustration is not to scale

• Corporate Office and R&D Centres in Noida, India • Discovery Centre in Bangalore, India • 7 manufacturing facilities in India and 3 in North America

Dusseldorf, Germany Jubilant Clinsys, Europe office

Ottawa, Canada DDDS office

Malvern, Pennsylvania, USA DDDS Office

Horsham, Pennsylvania Jubilant Cadista - Sales & Marketing Head Office

Raleigh North Carolina, USA Clinical Research Centre and Jubilant Life Sciences Marketing Office

4

5 5

Key Financials

461

639 723 770

892

0

500

1000

FY08 FY09 FY10 FY11 FY12

106 124

175 127

186

0

100

200

300

FY08 FY09 FY10 FY11 FY12

US$

Mn

US$

Mn

For FY 2012: 1 USD = 47.95 INR || For FY 2011: 1 USD=44.60 || For previous years : 1 USD=46.53

REVENUE EBITDA

Sustained growth momentum

6

Business Segments

Jubilant Life Sciences

Life Science Ingredients Mix: 49%

Life Science Chemicals Mix: 22%

Proprietary & Nutrition Ingredients Mix: 27%

APIs, Generics, Specialty Mix: 30%

CMO & CRO Mix: 21%

Presence across the Value Chain in Pharmaceuticals and Life Science Ingredients 6

Pharmaceuticals Mix: 51%

6

7

Profile Growth Drivers • Focus Areas

• APIs & Generics – CNS & CVS • Radiopharmaceuticals – diagnostic products • CMO - sterile injectibles, non sterile products

• Key growth markets – Regulated international markets

• Clients

• Diversified client base

• Products • Diversified product base

• USFDA approved manufacturing facilities in

• India, USA, Canada

• Strong product pipeline • 135 launches globally over 3 years • 58 DMF and 50 ANDAs filed in US

• Geographic expansion

• Europe, Japan, Emerging markets • Penetration in North America

• Increased capacity utilization

• In APIs, Generics, CMO -sterile injectibles

• Clinical Trials • CMO - extended service offerings in lab

trials for commercial products • DDDS - Collaborative programs in discovery

& development

Business Segments Pharmaceuticals Segment – Profile & Growth drivers

Offering products and services in niche segments for top-end clients 7

8

Profile Growth Drivers • Offers Products for Industrial applications

• Pharmaceuticals & Agrochemicals • Personal care, Food and Feed • Packaging, Textiles, Dyes, Inks

• Vertically integrated in-house technology

• Green feedstock for value added end products • Proprietary Products and Exclusive Synthesis –

Pyridines & derivatives • Nutrition Ingredients – Niacinamide (vitamin B3)

• Key growth markets – Europe, Emerging Markets

• GMP compliant Manufacturing facilities in India

• Clients • Diversified client base

• Proprietary Products and Exclusive Synthesis - product launches including

• Symtet, Pyridine based ingredient for insecticide

• Geographic expansion • Europe, USA, China & ROW

• Higher Capacity Utilization

• Nutrition Ingredients - Vitamin B3 for Animal & Human Nutrition

• Proprietary Products and Exclusive Synthesis – Symtet, Pyridines

• Life Science Chemicals - Ethyl Acetate & Acetic Anhydride

• Ongoing R&D of new product applications for

future growth

Business Segments Life Science Ingredients Segment – Profile & Growth drivers

Integrated player with low cost manufacturing for the Ingredients market 8

9

Global leadership in chosen lines of business

Pharmaceuticals

• APIs – Globally No. 1 in 4 APIs; and ranked among Top 3 in 3 APIs

• Generics - No. 1 in US in 3 products ; and ranked among Top 3 in 5 products

• Radiopharmaceuticals – No. 1 in North America in 3 Nuclear Medicine products

• Allergy Immunotherapy - Ranked among top 3 suppliers in North America

• CMO – Ranked among top 5 Contract Manufacturers in North America in sterile injectibles

Life Science Ingredients

• PPES - Globally No. 1 in Pyridines & 14 derivatives

• Nutrition Ingredients - Globally No. 2 in Niacinamide

• Life Science Chemicals - Globally No. 7 in Ethyl Acetate and Acetic Anhydride

Leadership Positions in Niche Markets 9

10

Strategic Objectives

• Global leadership in chosen lines of business

• Expanding innovative product portfolio, strengthened by in-house R&D

• Expanding geographic outreach

• Creating and pursuing growth opportunities

• High growth, high margin defensive Pharmaceuticals business

• Vertical integration

• Sustainability through Green initiatives

• Higher returns to shareholders

10

Expanding Product portfolio

11

Nutrition Ingredients Niacinamide, Niacin

Creating and pursuing growth opportunities Value Addition through Vertical Integration

Life Science Chemicals Alcohol (own production / purchased)

Methanol, Acetaldehyde, Formaldehyde

Life Science Ingredients

Proprietary Products and Exclusive Synthesis Pyridines, Derivatives, Symtet,

Beta Picoline, 3-Cyano Pyridine, >40 advance intermediates

APIs (own production / purchased)

Pharmaceuticals

Vertical Integration enables cost competitive advantage and higher margins

Generics

11 11

12

Innovation & Continuous Improvement

• Expertise in development of non-infringing processes for APIs and Dosage forms

• Strong IPR and Regulatory Affairs • High skill and low cost operation • Large number of process patent

applications filed • Three-platform technologies

developed for taste masking, orally disintegrating, and delayed release

• Ability to do specialized formulations and design equipments for radiopharmaceuticals

• Improvement in efficiency norms

• World class supply chain management leading to reduced working capital

• Operational improvement through employee participation

• Investment in R&D for new product/process development

• Capacity increase through de-bottlenecking

Culture of Innovation Continuous cost improvements

Providing innovative products and economically efficient solutions 12

13

Lean management & Six Sigma

• Removing process inefficiencies

• Addressing process variation

• Alignment to customer requirement

• Improve plant effectiveness & asset utilization through Total Productivity Management

Manufacturing Excellence

Design Excellence

Customer Excellence

Business Excellence Continuous Improvement Culture & Quality

Project Management

• Effective time and cost management for customer’s new product development projects

Customer dashboard & forecasting

• Analytics for better business decision making and forecasting accuracy

Design for Six Sigma (DFSS)

• Cut in cycle time of product development and process development

Amongst the lowest cost producers globally for most products in our portfolio 13

14

Creating and pursuing growth opportunities Corporate Sustainability

Sustainability Strategy Triple Bottom line Approach of Economic, Environment and Social Performance

Global Reporting Initiative (GRI)

• Rated A+ by GRI for six consecutive years, highest possible rating

• Top 2 in India as per Carbon Disclosure Project 2010- India 200 Report

Green Products*

• Green Products are produced in ecologically beneficial way •Customer’s first preference to bring more value through lower GHG emissions

•JLL Revenue from Green Products at 37% of Revenues in FY12, expected to grow at a CAGR of over 18% between FY12-FY15

* Green Products are produced with lower eco-footprints as compared to alternative route, done mainly through use of eco-friendly raw materials, potential reuse of wastes, bio-energy and cogeneration

Sustainability through Green Initiatives 14

15

Corporate social responsibility is the commitment of businesses to contribute towards inclusive growth

Mission & Purpose

• To contribute towards improving the quality of life of the community around its manufacturing locations and develop mutual trust and cordial relationships

• To bring more focus to this area of social interventions, Jubilant Bhartia Foundation, a not for profit company was launched in 2007 to carryout various social initiatives

• As a part of the Jubilant Bhartia Group, the foundation focuses on conceptualizing and implementing the Corporate Social Responsibility initiatives for the group

Corporate Social Responsibility at Jubilant

15

16

Ø Recognizing and rewarding Indian Social entrepreneurs in collaboration with Schwab Foundation

Ø Providing scholarships in R&D

and technology sector

National and International

level

Manufacturing locations

(with community)

Objective Action

Ø Philanthropic mode to Community development mode

Ø Initiatives in line with MDGs

(Millennium Development Goals)

Fulfilling the role of a responsible corporate citizen by contributing

towards inclusive growth Inclusive

Growth

Ultimate Goal

Winning the trust of the community

CSR Spectrum

CSR Spectrum

16

17 17

Primary Education

•JBF initiated Muskaan project for strengthening the Government Rural Primary Education system at all manufacturing locations

•Recognized by District Administration

•Project extended to 100 schools

•Reaching out to 13,500 students; benefitting 65 Schools.

•Absenteeism dropped by 70%

•Dropout rate has declined drastically

•A sense of pride among villagers for having Muskaan school in their villages

Basic Healthcare

•To promote health seeking behaviour and provide effective basic healthcare to the community JBF initiated Health Projects at all Location catering 4,85,000 beneficiaries:

• Initiated community based pilot project ‘Swasthya Prahari’ in Public- Private-People Partnership (4P Model)

•‘Nirog Bachpan’- School health check-up programme

•Mobile/Static Clinic at all project locations for Basic diagnostic services, Basic medication and referrals Day Care facilities, DOTS for TB, ICTC for HIV

Livelihood Generation

•JBF has structured its livelihood framework for improving employability skills of youth.

•The four domains of the training programs catering to the individual needs are:

•Technical Literacy •Vocational Training •Life Skill Training •Subsistence Living Training

•Vocational Training Centres at all locations.

•Capacity to train 2000 youths every year for skill development

•Employment: 60% through Self employment and placement

Social Entrepreneur

of the Year Award

•The Jubilant Bhartia Foundation and The Schwab Foundation for Social Entrepreneurship collaborating annually since 2010 to select India‘s ‘Social Entrepreneur of The Year’

•Social Entrepreneurs are innovators who implement practical and sustainable solutions to address challenges in numerous areas including health, education, environment, access to technology and job creation

• Mr. Anshu Gupta, Goonj, conferred with the Social Entrepreneur of the Year India 2012

An initiative between CII and Jubilant Bhartia to build capacity while leveraging technology and innovation to improve productivity and the environmental footprint of agriculture

18

Our Vision & Values

Our Values

18

19

Updated in May 2013

Thank You Corporate Office 1-A, Sector-16A Noida-201301, UP, India Email:support@jubl.com For more Info : www.jubl.com

19